Human tumor necrosis factor receptor TR9
AssigneeHuman Genome Sciences, Inc.
InventorsJian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.
Claims24
An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about -40 to about 615 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about -39 to about 615 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 615 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (e) a nucleotide sequence encoding the mature TR9 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (f) a nucleotide sequence encoding the TR9 extracellular domain;
- (g) a nucleotide sequence encoding the TR9 transmembrane domain;
- (h) a nucleotide sequence encoding the TR9 intracellular domain;
- (i) a nucleotide sequence encoding the TR9 receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- a nucleotide sequence encoding the TR9 death domain;
- and
- (k) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), or (0).
An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) the nucleotide sequence of clone HIBEJ86R (SEQ ID NO:6);
- (b) the nucleotide sequence of clone HLlAA79R (SEQ ID NO:7);
- (c) the nucleotide sequence of clone HHFGD57R (SEQ ID NO:8);
- (d) the nucleotide sequence of clone HSABG38R (SEQ ID NO:9);
- (e) the nucleotide sequence of clone HHPDZ3 1R (SEQ ID NO:10);
- (f) the nucleotide sequence of a portion of the sequence shown in SEQ ID NO:1 wherein said portion comprises at least 50 contiguous nucleotides from nucleotide 500 to nucleotide 980;
- and
- (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), or (f) above.
An isolated TR9 polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of-.
- (a) amino acids from about −40 to about 615 in SEQ ID NO:2;
- (b) amino acids from about −3)9 to about 615 in SEQ ID NO:2;
- (c) amino acids from about 1to about 615 in SEQ ID NO :2;
- (d) the amino acid sequence of the TR9 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (e) the amino acid sequence of the mature TR9 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (f) the amino acid sequence of the TR9 receptor extracellular domain;
- (g) the amino acid sequence of the TR9 receptor transmembrane domain;
- (h) the amino acid sequence of the TR9 receptor *intracellular domain;
- (i) the ami;no acid sequence of the TR9 receptor intracellular and extracellular domains with all or part of the transmembrane domain deleted;
- (j) the amino acid sequence of the TR9 receptor death domain;
- and
- (k) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), (i), or 0).
An isolated polypeptide comprising an epitope-bearing portion of the TR9 receptor protein, wherein said portion is selected from the group consisting of:
- a polypeptide comprising amino acid residues from about 4 to about 81 in SEQ ID NO:2;
- a polypeptide comprising amino acid residues from about 116 to about 271 in SEQ ID NO:2;
- a polypeptide comprising amino acid residues from about 283 to about 308 in SEQ ID NO:2;
- a polypeptide comprising amino acid residues from about 336 to about 372 in SEQ ID NO:2;
- a polypeptide comprising amino acid residues from about 393 to about 434 in SEQ ID NO:2;
- a polypeptide comprising amino acid residues from about 445 to about 559 in SEQ ID NO:2;
- and a polypeptide comprising amino acid residues from about 571 to about 588 in SEQ ID NO:2.
An isolated nucleic acid molecule comprising a polynucleotide encoding a TR9 receptor polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about −40 to about 615 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about −39 to about 615 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about I to about 615 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (e) a nucleotide sequence encoding the mature TR9 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (f) a nucleotide sequence encoding the TR9 extracellular domain;
- (g) a nucleotide sequence encoding the TR9 transmembrane domain;
- (h) a nucleotide sequence encoding the TR9 intracellular domain;
- (i) a nucleotide sequence encoding the TR9 receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- a nucleotide sequence encoding the TR9 death domain;
- and
- (k) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), or ()).
An isolated TR9 receptor polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of:
- (a) amino acids from about −40 to about 615 in SEQ ID NO:2;
- (b) amino acids from about −39 to about 615 in SEQ ID NO:2;
- (c) amino acids from about 1 to about 615 in SEQ ID NO:2;
- (d) the amino acid sequence of the TR9 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037:
- (e) the amino acid sequence of the mature TR9 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209037;
- (f) the amino acid sequence of the TR9 receptor extracellular domain;
- (g) the amino acid sequence of the TR9 receptor transmembrane domain;
- (h) the amino acid sequence of the TR9 receptor intracellular domain;
- (i) the amino acid sequence of the TR9 receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- j) the amino acid sequence of the TR9 receptor death domain;
- and
- (k) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), (i), or
Dependencies are inferred from the claim text.